ArticleThe oncologist2011

Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers.

Alex A Adjei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.